探讨沙格列汀联合二甲双胍对2型糖尿病患者血糖控制率的影响  

The effect of saxagliptin combined with metformin on blood glucose control rate in patients with type 2 diabetes mellitus

作　　者：苏慧 张华 SU Hui;ZHANG Hua(Yishui County People's Hospital,Linyi 276400,China)

机构地区：[1]沂水县人民医院,276400 [2]沂水县黄山铺镇卫生院,276400

出　　处：《中国现代药物应用》2024年第6期29-33,共5页Chinese Journal of Modern Drug Application

摘　　要：目的探讨2型糖尿病患者采用沙格列汀联合二甲双胍进行治疗的有效性。方法113例2型糖尿病患者,以信封法形式分为对照组(56例)和观察组(57例)。对照组给予口服二甲双胍治疗,观察组在对照组基础上联合口服沙格列汀治疗。比较两组患者治疗前后糖代谢情况、胰岛功能、机体微炎状态、血脂、生存质量。结果治疗后,观察组患者平均血糖(7.82±0.56)mmol/L、血糖标准差(1.59±0.12)mmol/L、平均血糖波动幅度(3.12±0.28)mmol/L均低于对照组的(9.95±1.03)、(2.03±0.21)、(5.20±0.17)mmol/L,血糖控制率78.95%高于对照组的55.36%(P<0.05)。治疗后,观察组患者空腹胰岛素(17.16±1.25)mU/L、胰岛素抵抗指数(5.86±0.37)均低于对照组的(19.39±1.01)mU/L、(7.90±0.58)(P<0.05)。治疗后,观察组C反应蛋白(CRP)(6.72±1.19)mg/L、白细胞介素-6(IL-6)(9.61±1.53)pg/ml、白细胞介素-1β(IL-1β)(11.90±0.63)pg/ml均低于对照组的(8.29±1.03)mg/L、(11.89±1.05)pg/ml、(13.45±0.77)pg/ml(P<0.05)。治疗后,观察组总胆固醇(5.23±1.15)mmol/L、甘油三酯(2.21±0.19)mmol/L、低密度脂蛋白胆固醇(2.75±0.33)mmol/L均低于对照组的(6.78±1.60)、(3.32±0.37)、(3.98±0.39)mmol/L(P<0.05)。治疗后,观察组患者疾病、生理、心理、社会、满意度评分分别为(1.61±0.20)、(2.15±0.29)、(2.56±0.18)、(2.02±0.13)、(1.73±0.11)分,均低于对照组的(3.57±0.28)、(3.65±0.45)、(3.67±0.12)、(3.18±0.15)、(3.12±0.29)分(P<0.05)。结论对2型糖尿病患者给予沙格列汀联合二甲双胍治疗效果明确,其能够改善患者糖代谢、胰岛功能,调节血脂水平,抑制机体微炎因子的释放,利于预后,值得推广应用。Objective To explore the effectiveness of saxagliptin combined with metformin on blood glucose control rate in patients with type 2 diabetes mellitus.Methods 113 patients with type 2 diabetes mellitus were divided into a control group(56 cases)and an observation group(57 cases)by envelope method.The control group was treated with oral metformin,while the observation group was treated with saxagliptin on the basis of the control group.The glucose metabolism,islet function,body micro inflammatory status,blood lipid,and quality of life were compared between the two groups before and after treatment.Results After treatment,the observation group had mean blood glucose of(7.82±0.56)mmol/L,standard deviation of blood glucose of(1.59±0.12)mmol/L,and mean blood glucose fluctuation of(3.12±0.28)mmol/L,which were lower than(9.95±1.03),(2.03±0.21)and(5.20±0.17)mmol/L in the control group;the observation group had higher blood glucose control rate of 78.95%than 55.36%in the control group(P<0.05).After treatment,the observation group had fasting insulin of(17.16±1.25)mU/L and insulin resistance index of(5.86±0.37),which were lower than(19.39±1.01)mU/L and(7.90±0.58)in the control group(P<0.05).After treatment,the observation group had C-reactive protein(CRP)of(6.72±1.19)mg/L,interleukin-6(IL-6)of(9.61±1.53)pg/ml,and interleukin-1β(IL-1β)of(11.90±0.63)pg/ml,which were lower than(8.29±1.03)mg/L,(11.89±1.05)pg/ml,and(13.45±0.77)pg/ml in the control group(P<0.05).After treatment,the observation group had total cholesterol of(5.23±1.15)mmol/L,triglyceride of(2.21±0.19)mmol/L and low-density lipoprotein cholesterol of(2.75±0.33)mmol/L,which were lower than(6.78±1.60),(3.32±0.37)and(3.98±0.39)mmol/L in the control group(P<0.05).After treatment,the scores of disease,physiology,psychology,society and satisfaction in the observation group were(1.61±0.20),(2.15±0.29),(2.56±0.18),(2.02±0.13)and(1.73±0.11)points,which were lower than(3.57±0.28),(3.65±0.45),(3.67±0.12),(3.18±0.15)and(3.12±0.29)points in the

关 键 词：沙格列汀 二甲双胍 2型糖尿病 血糖控制率 

分 类 号：R587.1[医药卫生—内分泌] R969[医药卫生—内科学]